Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHMT1 | P34896 | 3/20 | 0.48 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6481421 | 0.90 | THRB (0.46) | SMN1; SMN2ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL6475294 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL4424929 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL4435090 | 0.83 | LPAR1 (0.41) | SMN1; SMN2ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL6473687 | 0.80 | LPAR1 (0.42) | SMN1; SMN2ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL6475063 | 0.80 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL4428390 | 0.79 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL31446274 | 0.78 | AKR1B1 (0.67) | SMN1; SMN2ALDH1A1LMNATHRB | |
| SCHEMBL4435429 | 0.78 | AKR1B1 (0.67) | SMN1; SMN2ALDH1A1LMNATHRB | |
| SCHEMBL4433288 | 0.78 | TAS1R3 (0.42) | SMN1; SMN2ALDH1A1LMNATHRBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939888-B2 | 1-H-3-arylpirrolidine-2,4-dione derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-09-06 | — | — | US | disclosed |
| US-20040019061-A1 | 1-H-3-arylpirrolidine-2,4-dione derivatives | FISCHER REINER (DE) | 2004-01-29 | — | — | US | disclosed |
| US-6472419-B1 | 1-H-3-aryl-pyrrolidine-2, 4-dione derivatives as pest-control agents | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019061-A1 | 1-H-3-arylpirrolidine-2,4-dione derivatives | PRXL2A, DDT, CYP4B1 | SHMT1 4110/4885SHMT2 3637/4885SMN1; SMN2 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.